Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwAL 2025 | Key genomic and epigenetic drivers of clonal evolution in therapy-related myeloid neoplasms

Koichi Takahashi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the key genomic and epigenetic drivers of clonal evolution in therapy-related myeloid neoplasms. Dr Takahashi highlights the importance of P53 mutations, which have the highest leukemic potential, and suggests potential mechanisms for clonal evolution. This interview took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

From genetically, we definitely learned that P53 mutated clonal hematopoiesis really has the highest leukemic potential. But the question is, from our study, is that one patient can have multiple different types of P53 mutated clones, and theoretically, each clone has almost equal potential to become leukemia, but only one becomes leukemia. And the question is, what determines that? And one finding that we found is that additional chromosomal abnormality, particularly if you lose the other allele of p53, that really determines the transformation...

From genetically, we definitely learned that P53 mutated clonal hematopoiesis really has the highest leukemic potential. But the question is, from our study, is that one patient can have multiple different types of P53 mutated clones, and theoretically, each clone has almost equal potential to become leukemia, but only one becomes leukemia. And the question is, what determines that? And one finding that we found is that additional chromosomal abnormality, particularly if you lose the other allele of p53, that really determines the transformation. But then what exactly determines that is another question. And I think there will be some epigenetic component that in our study we couldn’t really tease that out because we really focused on the genetic analysis. But I think the future question and future project will focus on epigenetic determinants of clonal selection.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.